Increasing the number of cycles of chemotherapy doesn’t appear to significantly influence recurrence rates or survival in patients with early stage ovarian clear cell carcinoma (OCCC), according to researchers.
The retrospective cohort study of 201 patients showed that recurrence and … Read more
Tesaro has opened an expanded access program (EAP) in the United States for their investigational poly ADP ribose polymerase (PARP) inhibitor, niraparib.
Now, niraparib is can be available, to treat a patient who meet certain criteria, with a serious disease … Read more
As we step into 2017, a big question looming in the minds of all stakeholders in the cancer research arena is: What is the future of cancer research in the new administration? Members of Congress on both sides of the … Read more
Fewer than half of women diagnosed with ovarian cancer live for five years or more. Sarah Adams, MD, a cancer doctor at the UNM Comprehensive Cancer Center, hopes a new therapy that delivers a one-two punch to cancer cells will … Read more
By: Annette McElhiney
Many of you have already read Dr. Maurie Markman’s article “In Ovarian Cancer Advancements, Finding New Biomarkers is Key” posted in the Clearity blog. It provoked me as an ovarian cancer survivor and non-medical professional … Read more
The search for validated, actionable biomarkers may be more important than initiating more phase 3 trials in the field of ovarian cancer, according to Maurie Markman, M.D.
“In the ovarian cancer arena, we have 30 years of history of doing … Read more
Testing for a gene commonly mutated in ovarian cancers could pick out patients who will respond well to a promising new class of cancer drugs, a major new study reveals.
Scientists found that defects in a gene called ARID1A caused … Read more
Heavily pre-treated patients with recurrent ovarian cancer have limited options when it comes to regimens that can control disease while maintaining a satisfactory quality of life.
Now, a phase II open-label study has demonstrated that a combination of the camptothecin … Read more
Two thin tubes that connect the ovaries to the uterus have assumed an outsize role in the battle against ovarian cancer. Research increasingly points to the likelihood that some of the most aggressive ovarian cancers originate in the fallopian tubes. … Read more
The U.S. Food and Drug Administration (FDA) today granted accelerated approval to rucaparib (Rubraca) to treat women with advanced ovarian cancer who have been treated with two or more chemotherapies and whose tumors have a specific gene mutation (deleterious BRCA… Read more
Delivering bad news to a patient is one of the toughest parts of being a medical professional. As an ob/gyn, whenever I had a patient that showed signs of ovarian, cervical or uterine cancer, it was my responsibility to inform … Read more
Arkansas, California, Florida, Maine, Massachusetts, Nevada, and North Dakota passed some form of marijuana legalization on Election Day 2016, potentially reducing barriers for patients with cancer hoping to use marijuana to relieve symptoms of pain or to increase appetite as … Read more
There has been major progress in treating gynecologic malignancies in recent years, especially for ovarian cancer, says Douglas A. Levine, M.D., a member of The Clearity Foundation’s Scientific Advisory Board.
For example, PARP inhibition has gained impressive traction as a … Read more
Lynparza (olaparib) demonstrated improved progression-free survival (PFS) compared to the placebo arm for patients with ovarian cancer, according to findings from the phase 3 SOLO-2 trial. The single-agent PARP inhibitor was tested in the maintenance setting for patients with advanced … Read more
Ovarian cancer is among the 3 most common gynecologic cancers, along with cervical and endometrial cancers. According to the American Cancer Society, 1 in 75 women will have ovarian cancer in their lifetime, about 22,280 women will be diagnosed with … Read more
Stress and depression not only affect the quality of life of women with ovarian cancer, but it can also have a negative impact on their prognosis, according to Susan Lutgendorf, Ph.D., professor and Starch Faculty Fellow at the University of … Read more
Academic scientists devote their lives to research, often toiling away on problems that few people outside their discipline fully understand. Perhaps some are driven by pure curiosity or competition, while others have a personal interest in the topic at hand.… Read more
In the crucible of cancer treatment, the bonding of patients with physicians often makes the unendurable endurable. The difficulty of finding and then keeping the right oncologist can therefore be fraught. Yet this problem, not uncommon today, is on track … Read more
Annually, Support Connection, a a not-for-profit organization that provides emotional, social and educational support to women, their families and friends affected by breast and ovarian cancer, hosts a webinar/teleconference.
In September 2015, our founder Dr. Laura Shawver hosted a webinar … Read more
As its name suggests, baby powder, a talcum powder blend that absorbs moisture and reduces chafing, used to be a common staple of diaper changing stations in homes all across America.
But Johnson & Johnson, the company that makes the … Read more
